3SBio Inc. Announces Unaudited Second Quarter 20...(US$6.3 million) on a GAAP basis and incr...),Health

Date:8/11/2009

US$6.3 million) on a GAAP basis, and increased 15.3% over the first half of 2008 to RMB47.7 million (US$7.0 million) on a non-GAAP basis. -- Net income per ADS for the first half of 2009 was RMB1.99 (US$0.29) compared with RMB1.80 (US$0.26) for the first half of 2008 on a GAAP basis, and RMB2.21 (US$0.32) compared with RMB1.90 (US$0.28) for the first half of 2008 on a non-GAAP basis. Second Quarter 2009 Business Highlights -- EPIAO, the Company's flagship injectable recombinant human erythropoietin ("EPO") products, demonstrated strong growth with net revenue from EPIAO rising 37.6% over the second quarter of 2008 to RMB51.1 million (US$7.5million) in the second quarter of 2009. -- TPIAO net revenue increased by 38.4% to RMB22.2million (US$3.3 million) in the second quarter of 2009. TPIAO, the Company's protein-based therapeutic recombinant human thrombopoietin ("TPO") product. -- 3SBio continued to work closely with the State Food and Drug Administration ("SFDA") to advance the regulatory approval of the three new product programs submitted in 2008: 36,000 IU dosage formulation of EPIAO, NuLeusin, and TPIAO label extension for the treatment of ITP. -- Construction continued on schedule for the Company's new EPIAO plant, which will support the future growth of EPIAO and serve as the first step towards exploring global biosimilar opportunities. In June, Mr Deyu Kong joined 3SBio as Director -- Manufacture and Process, and will be based in Shenyang. Mr Kong brings a wealth of manufacturing experience under US and EU compliant manufacturing environments. -- While exports account for a small portion of revenue and the company remains focused on its core business in China, 3SBio and its products EPIAO and TPIAO continue to be recognized by more physicians and patients
'/>"/>

SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Related medicine news :

1. 3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
2. 3SBio Inc. Announces Unaudited First Quarter 2009 Results
3. 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
4. 3SBio Inc. Announces Filing of Annual Report on Form 20-F
5. 3SBio Inc. to Present at The CIBC World Markets 18th Annual Healthcare Conference
6. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
7. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. Leading Medical Developer Announces Plans for Texoma Medical Plaza
10. iMedX Announces Investment of $13M From RFE Investment Partners
11. Health Market Science Announces Commercial Release of CompleteSpend V2.5